Table 1

Baseline and demographic characteristics in the evaluable population

CharacteristicExenatide QW 2 mg (n = 29)Exenatide QMS 5 mg (n = 26)Exenatide QMS 8 mg (n = 28)Exenatide QMS 11 mg (n = 27)Total (N = 110)
Male sex, n (%)19 (65.5)15 (57.7)23 (82.1)15 (55.6)72 (65.5)
Age, years49.0 ± 9.850.0 ± 10.152.3 ± 10.749.9 ± 10.650.3 ± 10.2
Race, n (%)
 White27 (93.1)21 (80.8)26 (92.9)21 (77.8)95 (86.4)
 Black1 (3.4)3 (11.5)2 (7.1)4 (14.8)10 (9.1)
 Asian0 (0.0)1 (3.8)0 (0.0)2 (7.4)3 (2.7)
 Native Hawaiian or Pacific Islander0 (0.0)1 (3.8)0 (0.0)0 (0.0)1 (0.9)
 Other1 (3.4)0 (0.0)0 (0.0)0 (0.0)1 (0.9)
Body weight, kg101.1 ± 20.492.4 ± 17.1102.7 ± 16.095.4 ± 19.698.1 ± 18.6
BMI, kg/m233.8 ± 5.433.4 ± 6.034.0 ± 6.033.8 ± 5.733.8 ± 5.7
Duration of diabetes, years6.0 ± 5.55.0 ± 3.66.4 ± 5.96.7 ± 5.86.0 ± 5.3
HbA1c, %8.63 ± 1.218.42 ± 1.148.61 ± 1.228.36 ± 1.348.51 ± 1.22
HbA1c, mmol/mol71 ± 1369 ± 1371 ± 1368 ± 1570 ± 13
FPG, mg/dL186.6 ± 52.7182.0 ± 37.0185.3 ± 39.5181.0 ± 46.9183.8 ± 44.1
SBP, mmHg131.4 ± 11.1128.9 ± 14.6128.5 ± 13.0122.0 ± 14.7NA
DBP, mmHg82.1 ± 6.979.3 ± 8.180.1 ± 9.076.5 ± 8.6NA
Creatinine clearance,* mL/min110.8 ± 26.294.8 ± 23.8106.0 ± 31.2103.1 ± 35.0103.9 ± 29.6
Diabetes management, n (%)
 Diet/exercise3 (10.3)2 (7.7)10 (35.7)5 (18.5)20 (18.2)
 Metformin21 (72.4)19 (73.1)14 (50.0)22 (81.5)76 (69.1)
 Pioglitazone1 (3.4)1 (3.8)1 (3.6)0 (0.0)3 (2.7)
 Metformin + pioglitazone4 (13.8)4 (15.4)3 (10.7)0 (0.0)11 (10.0)
Patients with hypertension, n (%)16 (55.2)12 (46.2)14 (50.0)12 (44.4)54 (49.1)
Concomitant β-blockers, n (%)2 (6.9)5 (19.2)4 (14.3)2 (7.4)13 (11.8)
  • Data are mean ± SD, unless otherwise noted.

  • NA, not applicable.

  • *Cockcroft-Gault creatinine clearance;

  • †Patients with hypertension were defined as patients with baseline BP >140/90 mmHg or patients who had taken any of the following antihypertensive medications at baseline: vasodilators, antihypertensive agents, diuretics, β-blocking agents, calcium channel blockers, or agents acting on the renin-angiotensin system.